Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Target disruption of the mutant β-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype

Abstract

Most colorectal carcinomas harbor genetic alterations that result in stabilization of β-catenin. A colorectal carcinoma cell line, HCT116, which has both mutated and wild-type β-catenin genes, was engineered by homologous recombination to investigate the significance of β-catenin gene mutation. As expected, the mutant allele-targeted clones showed decreased β-catenin expression and downregulation of T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription. Morphologically, targeted clones were only minimally altered under usual culture conditions, but under low serum conditions, mutant allele-targeted clones still grew in plane, in contrast to parental cell line and wild allele-targeted clones, which formed spheroids. The mutant allele-targeted clones showed no significant changes in growth rate and anchorage-independent growth in vitro, and displayed rather increased growth in vivo. Although β-catenin stabilization affects some biological characteristics including adhesive properties, it may not have growth-promoting effects at least in some colorectal carcinomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis B, Matrisian LM . 1999 Oncogene 18: 2883–2891

  • Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM . 1999 EMBO J. 18: 5931–5942

  • He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW . 1998 Science 281: 1509–1512

  • Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC . 2000 J. Clin. Invest. 106: 533–539

  • Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN . 2000 Nat. Genet. 26: 146–147

  • Mariadason JM, Bordonaro M, Aslam F, Shi L, Kuraguchi M, Velcich A, Augenlicht LH . 2001 Cancer Res. 61: 3465–3471

  • Nagasawa Y, Miyoshi Y, Iwao K, Shinomura Y, Matsuzawa Y, Nakamura Y . 1999 Cancer Res. 59: 3539–3542

  • Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S . 2001 Cancer Res. 61: 2751–2758

  • Orford K, Orford CC, Byers SW . 1999 J. Cell Biol. 146: 855–868

  • Polakis P . 2000 Genes Dev. 14: 1837–1851

  • Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA . 2001 Cancer Res. 61: 6563–6568

  • Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Mutata M, Shimano T, Yamaoka Y, Nakamura Y . 2000 Nat. Genet. 24: 245–250

  • Sedivy JM, Dutriaux A . 1999 Trend Genet. 15: 88–90

  • Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, Hirohashi S . 2002 Virchows. Arch. 440: 381–386

  • Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T, Toyoshima K, Kanamaru R, Kanegae Y, Saito I, Nakamura Y, Noda T . 1997 Science 278: 120–123

  • Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B . 2001 Cancer Res. 61: 818–822

  • Shirasawa S, Furuse M, Yokoyama N, Sasazuki T . 1993 Science 260: 85–88

  • Sparks AB, Morin PJ, Vogelstein B, Kinzler KW . 1998 Cancer Res. 58: 1130–1134

  • Tetsu O, McCormick F . 1999 Nature 398: 422–426

  • Wagenaar RA, Crawford HC, Matrisian LM . 2001 Cancer Res. 61: 2097–2104

  • Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM . 1997 Proc. Natl. Acad. Sci. USA 94: 1402–1407

  • Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S . 2000 Cancer Res. 60: 4761–4766

Download references

Acknowledgements

We thank Drs Gen Fujii, Tesshi Yamada, Yasuyoshi Naishiro and Masaaki Takamura for technical advice. This work was supported in part by a Grant-in-Aid for Second Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Setsuo Hirohashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sekine, S., Shibata, T., Sakamoto, M. et al. Target disruption of the mutant β-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene 21, 5906–5911 (2002). https://doi.org/10.1038/sj.onc.1205756

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205756

Keywords

This article is cited by

Search

Quick links